Study: Need for diabetes educators likely to rise
CHICAGO — The need for diabetes educators will rise sharply between now and 2025 as the diabetes epidemic worsens, according to a new study by the American Association of Diabetes Educators.
The study, conducted by Dobson DaVanzo & Associates, found that the need would increase by at least 60% over the next 14 years, with new career opportunities likely to emerge as private insurers and Medicare recognize the role the educators play.
As this happens, the range of work settings for diabetes educators will expand and include retail clinics, home health and long-term care centers and others in addition to hospital outpatient and physician office positions.
"The research confirms that diabetes education is a growing and vitally important healthcare specialty," AADE CEO Lana Vukovljak said. "Diabetes education, in addition to being a public health benefit, is a proven way to reduce healthcare costs."
In addition, payers are likely to view diabetes education more favorably, thanks to the growing body of literature supporting its cost effectiveness and the trend toward greater integration in health care.
The study included literature review, a search of employment websites to find job postings for diabetes educators, a claims analysis using Medicare claims from 2006-2009 and the development of a quantitative workforce model of the supply and demand for educators through 2025.
Lannett ships morphine product
PHILADELPHIA—Lannett has started shipping a painkiller product approved by the Food and Drug Administration in June, the company said.
Lannett announced the shipment of morphine sulfate oral solution. Lannett sought FDA approval using a 505(b)(2) new drug application. Sales of morphine sulfate oral solution at average wholesale price were $31.7 million during the 12-month period ending in June, according to Wolters Kluwer.
"This is our first drug approval using a 505(b)(2) application," Lannett president and CEO Arthur Bedrosian said. "We have received orders from drug wholesalers, nursing home providers and distributors."
No comments found
Chain Drug Consortium opposes ESI-Medco merger
BOCA RATON, Fla. — The Chain Drug Consortium on Thursday dispensed a formal letter to the U.S. Federal Trade Commission expressing its opposition to the proposed merger of pharmacy benefit management companies Express Scripts and Medco Health Solutions.
The correspondence indicated the consortium’s opposition based on the merger’s negative effect on the consumer public, patients and pharmacies, as a result of exercising undue market power over the brand and generic prescription drug supply chain. "We are greatly concerned that the planned merger will dilute patient care and restrict patient choice to pharmacy access,” stated Edward Frisch, Chain Drug Consortium president and CEO.
The Chain Drug Consortium consists of 18 retail chain members, representing more than 1,150 stores, more than 2,300 pharmacists and more than 40,000 employees.
No comments found